PMID- 9631585
OWN - NLM
STAT- MEDLINE
DCOM- 19980709
LR  - 20191024
IS  - 0925-5710 (Print)
IS  - 0925-5710 (Linking)
VI  - 67
IP  - 2
DP  - 1998 Feb
TI  - A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) 
      after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and 
      mitoxantrone, and the alkylating agent, cyclophosphamide.
PG  - 179-86
AB  - A 59-year-old female suffering from malignant lymphoma developed therapy-related 
      acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment 
      with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and an 
      alkylating agent, cyclophosphamide. The cumulative dose of etoposide 
      administration was 5500 mg; 1500 mg given intravenously and 4000 mg orally. One 
      year later, she suddenly developed AML of FAB M2. Cytogenetic analysis of bone 
      marrow cells revealed deletion of 7q and a rare translocation, t(16;21)(q24;q22). 
      Southern blot analysis of bone marrow cells did not detect rearrangement of the 
      AML1 gene, however, fluorescence in situ hybridization (FISH) analysis of bone 
      marrow cells at interphase and metaphase revealed a translocational splitting 
      between chromosome 21 involving AML1 gene and chromosome 16. These results 
      suggest that the breakpoint is not located in the breakpoint cluster region for 
      t(8;21). The patient was treated with chemotherapy and entered complete 
      remission.
FAU - Takeda, K
AU  - Takeda K
AD  - Department of Medicine, Yamaguchi Prefecture Central Hospital, Hofu, Japan.
FAU - Shinohara, K
AU  - Shinohara K
FAU - Kameda, N
AU  - Kameda N
FAU - Ariyoshi, K
AU  - Ariyoshi K
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Alkylating Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA Probes)
RN  - 0 (Topoisomerase II Inhibitors)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - BZ114NVM5P (Mitoxantrone)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
RN  - VB0R961HZT (Prednisone)
RN  - CEMP protocol
SB  - IM
MH  - Alkylating Agents/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/*adverse effects/*therapeutic use
MH  - *Antineoplastic Combined Chemotherapy Protocols
MH  - Blotting, Southern
MH  - Chromosomes, Human, Pair 16/*genetics
MH  - Chromosomes, Human, Pair 21/*genetics
MH  - Cosmids/genetics
MH  - Cyclophosphamide/administration & dosage
MH  - DNA Probes/genetics
MH  - DNA Topoisomerases, Type II/adverse effects/therapeutic use
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Gene Deletion
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myeloid, Acute/chemically induced/*etiology/*genetics
MH  - Leukemia, Radiation-Induced/etiology
MH  - Middle Aged
MH  - Mitoxantrone/administration & dosage
MH  - Prednisone/administration & dosage
MH  - *Topoisomerase II Inhibitors
MH  - Translocation, Genetic/*genetics
EDAT- 1998/06/19 00:00
MHDA- 1998/06/19 00:01
CRDT- 1998/06/19 00:00
PHST- 1998/06/19 00:00 [pubmed]
PHST- 1998/06/19 00:01 [medline]
PHST- 1998/06/19 00:00 [entrez]
AID - S0925571097001084 [pii]
AID - 10.1016/s0925-5710(97)00108-4 [doi]
PST - ppublish
SO  - Int J Hematol. 1998 Feb;67(2):179-86. doi: 10.1016/s0925-5710(97)00108-4.